Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer

BJU International

Volumn 112, Issue 8, 2013, Pages 1096-1104

  O'Brien, Timothy ^a   Ray, Eleanor ^a   Chatterton, Kathryn ^a   Khan, Muhammad Shamim ^a   Chandra, Ashish ^a   Thomas, Kay ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

bladder cancer; flourescence; Hexvix ; photodynamic diagnosis; transurethral resection

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER; MITOMYCIN;

ADULT; AGED; ARTICLE; BLADDER TUMOR; BLUE LIGHT; CAMERA; CANCER DIAGNOSIS; CANCER SURGERY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; OCCULT CANCER; PHOTODYNAMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TRANSURETHRAL RESECTION; WHITE LIGHT;

BLADDER CANCER; FLOURESCENCE; HEXVIX®; PHOTODYNAMIC DIAGNOSIS; TRANSURETHRAL RESECTION;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; ANTIBIOTICS, ANTINEOPLASTIC; CYSTOSCOPY; FEMALE; FLUORESCENCE; HUMANS; LIGHT; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84887303089     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12355     Document Type: Article

References (27)

1. Babjuk M, Oosterlinck W, Sylvester R,. The European Association of Urology (EAU). EAU guidelines on non-muscle invasive urothelial carcinoma of the bladder- the 2011 update. Eur Urol 2011; 59: 997-1008
2. Brausi M, Collette L, Kurth K, et al.; EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002; 41: 523-531
3. Schwaibold HE, Sivalingham S, May F, Hartung R,. The value of a second transurethral resection for T1 bladder cancer. BJU Int 2006; 97: 1199-1201
4. Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F,. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 2010; 58: 185-190
5. Mariappan P, Finney SM, Head E, et al. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int 2012; 109: 1666-1673
6. Sylvester RJ, Oosterlinck W, van der Meijden AP, et al. A single immediate post-operative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004; 171: 2186-2190
7. Jichlinski P, Guillou L, Karlsen SJ, et al. Hexyl aminolevulinate fluorescence cystoscopy: a new diagnostic tool for the photodiagnosis of superficial bladder cancer: a multicentre study. J Urol 2003; 170: 226-229
8. Schmidbauer J, Witjes F, Schmeller N, et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004; 171: 135-138
9. Kausch I, Sommerauer M, Montorsi F, et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol 2010; 57: 595-606
10. Witjes JA, Redorta JP, Jacqmin D, et al. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur Urol 2010; 57: 607-614
11. Fradet Y, Grossman HB, Gomella L, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007; 178: 68-73
12. Grossman HB, Gomella L, Fradet Y, et al. A phase III multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007; 178: 62-67
13. Mowatt G, N'Dow J, Vale L, et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis. Int J Technol Assess Health Care 2011; 27: 3-10
14. Stenzl A, Burger M, Fradet Y, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010; 184: 1907-1914
15. Stenzl A, Penkoff H, Dajc-Sommerer E, et al. Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial. Cancer 2011; 117: 938-947
16. Geavlete B, Multescu R, Georgescu D, Jecu M, Stanescu F, Geavlete P,. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)? BJU Int 2012; 109: 549-556
17. Filbeck T, Pichlmeier U, Knuechel R, et al. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol 2002; 168: 67-71
18. Babjuk M, Soukup V, Petrik R, Jirsa M, Dvorácek J,. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int 2005; 96: 798-802
19. Grossman HB, Stenzl A, Fradet Y, et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 2012; 188: 58-62
20. Hermann GG, Mogensen K, Carlsson S, Marcussen N, Duun S,. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to lessresidual tumour tissue in Ta/T1 patients: a randomized two-centre study. BJU Int 2011; 108: 297-303
21. Ray E, Chatterton K, Thomas K, Khan S, Chandra A, O'Brien TS,. Hexylaminolevulinate photodynamic diagnosis for multifocal recurrent non muscle invasive bladder cancer. J Endourol 2009; 23: 983-988
22. Ray E, Chatterton K, Khan S, Thomas K, Chandra A, O'Brien TS,. Hexylaminolevulinate 'Blue Light' fluorescence cystoscopy in the investigation of clinically unconfirmed positive urine cytology. BJU Int 2009; 103: 1363-1367
23. Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006; 7: 43-51
24. Schulz KF, Altman DF, Moher D,. CONSORT 2010 statement-updated guidelines for reporting parallel group randomised trials. Ann Intern Med 2010; 152: 726-732
25. Thomas K, O'Brien TS,. Blue-sky thinking about blue light cystoscopy. BJU Int 2009; 104: 887-889
26. Gan C, Patel A, Fowler S, Rosario D, Catto J, O'Brien TS,. STUKA- A snapshot of transurethral resection of bladder cancer in the UK audit. BJU Int 2013; 112: 930-935
27. Di Stasi SM, Valenti M, Verri C, et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol 2011; 12: 871-879